Burkitt post-Transplantation lymphoma in adult solid organ transplant recipients: Sequential immunochemotherapy with rituximab (R) followed by cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or R-CHOP is safe and effective in an analysis of 8 patients

Cancer

Volumn 118, Issue 19, 2012, Pages 4715-4724

  Zimmermann, Heiner ^a   Reinke, Petra ^b   Neuhaus, Ruth ^b   Lehmkuhl, Hans ^c   Oertel, Stephan ^d   Atta, Johannes ^e   Planker, Manfred ^f   Gärtner, Barbara ^g   Lenze, Dido ^b   Anagnostopoulos, Ioannis ^b   Riess, Hanno ^b   Trappe, Ralf U ^a,b  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c DEUTSCHES HERZZENTRUM BERLIN   (Germany)

^d F HOFFMANN LA ROCHE LTD   (Switzerland)

^e UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^f Helios Hospital Krefeld   (Germany)

^g SAARLAND UNIVERSITY   (Germany)

Author keywords

Burkitt lymphoma; Burkitt PTLD; MYC; post Transplantation lymphoproliferative disorder; v myc myelocytomatosis viral oncogene homolog (avian)

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RITUXIMAB; TACROLIMUS; VINCRISTINE;

ADULT; ANEMIA; ARTICLE; BRAIN RADIATION; BURKITT LYMPHOMA; CANCER GRADING; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL FEATURE; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; ETHNIC GROUP; FEBRILE NEUTROPENIA; FEMALE; GERMAN; HUMAN; LEUKEMIA; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; ORGAN TRANSPLANTATION; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIOIMMUNOTHERAPY; RECIPIENT; RETROSPECTIVE STUDY; THROMBOCYTOPENIA;

ADULT; AGED; ALGORITHMS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BURKITT LYMPHOMA; CRANIAL IRRADIATION; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; FOLLOW-UP STUDIES; GERMANY; HUMANS; IMMUNOLOGIC FACTORS; IN SITU HYBRIDIZATION, FLUORESCENCE; INJECTIONS, SPINAL; MALE; MIDDLE AGED; ORGAN TRANSPLANTATION; PREDNISONE; REGISTRIES; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; VINCRISTINE;

EID: 84866499120     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27482     Document Type: Article

References (31)

1. Burkitt D,. A sarcoma involving the jaws in African children. Br J Surg. 1958; 46: 218-223.
2. Leoncini L, Raphael M, Stein H, Harris NL, Jaffe ES, Kluin PM,. Burkitt lymphoma. In:, Swerdlow SH, Campo E, Harris N, et al. eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: International Agency for Research on Cancer; 2008: 262-264.
3. Penn I, Hammond W, Brettschneider L, Starzl TE,. Malignant lymphomas in transplantation patients. Transplant Proc. 1969; 1: 106-112.
4. Swerdlow SH, Webber SA, Chadburn A, Ferry JA,. Post-Transplant lymphoproliferative disorders. In:, Swerdlow SH, Campo E, Harris NL, et al. eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: International Agency for Research on Cancer; 2008: 343-350.
5. Oertel SH, Verschuuren E, Reinke P, et al. Effect of Anti-CD 20 antibody rituximab in patients with post-Transplant lymphoproliferative disorder (PTLD). Am J Transplant. 2005; 5: 2901-2906.
6. Choquet S, Leblond V, Herbrecht R, et al. Efficacy and safety of rituximab in B-cell post-Transplant lymphoproliferative disorders: results of a prospective multicentre phase II study. Blood. 2006; 107: 3053-3057.
7. Trappe R, Oertel S, Leblond V, et al. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-Transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. Lancet Oncol. 2012; 13: 196-206.
8. Epstein MA, Achong BG, Barr YM,. Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet. 1964; 1: 702-703.
9. Klein E, Kis LL, Klein G,. Epstein-Barr virus infection in humans: from harmless to life endangering virus-lymphocyte interactions. Oncogene. 2007; 26: 1297-1305.
10. Klapproth K, Wirth T,. Advances in the understanding of MYC-induced lymphomagenesis. Br J Haematol. 2010; 149: 484-497.
11. Barrans S, Crouch S, Smith A, et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol. 2010; 28: 3360-3365.
12. Perkins AS, Friedberg JW,. Burkitt lymphoma in adults. Hematol Am Soc Hematol Educ Program. 2008: 341-348.
13. Hoffmann C, Wolf E, Wyen C, et al. AIDS-associated Burkitt or Burkitt-like lymphoma: short intensive polychemotherapy is feasible and effective. Leuk Lymphoma. 2006; 47: 1872-1880.
14. Oriol A, Ribera JM, Bergua J, et al. High-dose chemotherapy and immunotherapy in adult Burkitt lymphoma: comparison of results in human immunodeficiency virus-infected and noninfected patients. Cancer. 2008; 113: 117-125.
15. Kelly JL, Toothaker SR, Ciminello L, et al. Outcomes of patients with Burkitt lymphoma older than age 40 treated with intensive chemotherapeutic regimens. Clin Lymphoma Myeloma. 2009; 9: 307-310.
16. Barnes JA, Lacasce AS, Feng Y, et al. Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis. Ann Oncol. 2011; 22: 1859-1864.
17. Thomas DA, Faderl S, O'Brien S, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-Type lymphoma or acute lymphoblastic leukemia. Cancer. 2006; 106: 1569-1580.
18. Choquet S, Trappe R, Leblond V, et al. CHOP-21 for the treatment of post-Transplant lymphoproliferative disorders (PTLD) following solid organ transplantation. Haematologica. 2007; 92: 273-274.
19. Xicoy B, Ribera J-M, Esteve J, et al. Post-Transplant Burkitt's leukemia or lymphoma. Study of 5 cases treated with specific intensive therapy (PETHEMA ALL-3/97 trial). Leuk Lymphoma. 2003; 44: 1541-1543.
20. Gong JZ, Stenzel TT, Bennett ER, et al. Burkitt lymphoma arising in organ transplant recipients: a clinicopathologic study of 5 cases. Am J Surg Pathol. 2003; 27: 818-827.
21. Picarsic J, Jaffe R, Mazariegos G, et al. Post-Transplant Burkitt lymphoma is a more aggressive and distinct form of post-Transplant lymphoproliferative disorder. Cancer. 2011; 117: 4540-4550.
22. Trappe R, Choquet S, Oertel SHK, et al. Sequential treatment with rituximab and CHOP chemotherapy in B-cell PTLD-moving forward to a first standard of care: results from a prospective international multicenter trial [abstract]. Blood (ASH Annual Meeting Abstracts). 2009; 114. Abstract 100.
23. Oertel SH, Papp-Vary M, Anagnostopoulos I, et al. Salvage chemotherapy for refractory or relapsed post-Transplant lymphoproliferative disorder in patients after solid organ transplantation with a combination of carboplatin and etoposide. Br J Haematol. 2003; 123: 830-835.
24. Trappe R, Zimmermann H, Fink S, et al. Plasmacytoma-like post-Transplant lymphoproliferative disorder, a rare subtype of monomorphic B-cell post-Transplant lymphoproliferation, is associated with a favorable outcome in localized as well as in advanced disease: a prospective analysis of 8 cases. Haematologica. 2011; 96: 1067-1071.
25. Zimmermann H, Oschlies I, Fink S, et al. Plasmablastic posttransplant lymphoma: cytogenetic aberrations and lack of Epstein-Barr virus association linked with poor outcome in the prospective German Posttransplant Lymphoproliferative Disorder Registry [published online ahead of print January 9, 2012]. Transplantation. 2012.
26. Ziegler JL, Bluming AZ, Fass L, Morrow RH,. Relapse patterns in Burkitt's lymphoma. Cancer Res. 1972; 32: 1267-1272.
27. Smeland S, Blystad AK, Kvaloy SO, et al. Treatment of Burkitt's/Burkitt-like lymphoma in adolescents and adults: a 20-year experience from the Norwegian Radium Hospital with the use of 3 successive regimens. Ann Oncol. 2004; 15: 1072-1078.
28. Bernstein JI, Coleman CN, Strickler JG, Dorfman RF, Rosenberg SA,. Combined modality therapy for adults with small noncleaved cell lymphoma (Burkitt's and non-Burkitt's types). J Clin Oncol. 1986; 4: 847-858.
29. Dunleavy K, Pittaluga S, Janik J, et al. Novel Treatment of Burkitt lymphoma with dose-adjusted EPOCH-rituximab: preliminary results showing excellent outcome [abstract]. Blood (ASH Annual Meeting Abstracts). 2006; 108. Abstract 2736.
30. Wilson WH, Grossbard ML, Pittaluga S, et al. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood. 2002; 99: 2685-2693.
31. Reshef R, Vardhanabhuti S, Luskin MR, et al. Reduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder. Am J Transplant. 2011; 11: 336-347.